Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Pro Medicus Limited ( (AU:PME) ) is now available.
4DMedical Limited has secured a $10 million strategic investment from Pro Medicus, a leading medical imaging software company, to accelerate its commercial pipeline and advance its CT:VQ™ product towards regulatory clearance in the U.S. This investment, structured as a hybrid debt and equity loan, provides growth capital without diluting shares if 4DMedical’s share price remains stable, while aligning interests with Pro Medicus if the share price rises. The agreement also allows Pro Medicus to distribute 4DMedical products, potentially enhancing their market reach and operational capabilities.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
4DMedical Limited is a global medical technology company specializing in respiratory care through advanced imaging and AI-powered solutions. Their patented XV Technology® provides dynamic quantification of lung ventilation, aiding in early and precise diagnosis of respiratory diseases. Their solutions, including the FDA-cleared XV Lung Ventilation Analysis Software, integrate into existing hospital systems via a SaaS model, enhancing diagnostic capabilities. The company expanded its leadership in medical imaging with the acquisition of Imbio, which offers AI-driven platforms for chronic lung and cardiothoracic diseases.
Average Trading Volume: 188,312
Technical Sentiment Signal: Buy
Current Market Cap: A$33.76B
Learn more about PME stock on TipRanks’ Stock Analysis page.